Gossamer Bio Announces Promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs
April 16 2021 - 7:55AM
Business Wire
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage
biopharmaceutical company focused on discovering, acquiring,
developing and commercializing therapeutics in the disease areas of
immunology, inflammation and oncology, today announced the
promotion of Caryn Peterson to Executive Vice President, Regulatory
Affairs. In this role, Ms. Peterson will continue to lead
Gossamer’s Regulatory and Quality functions, tasked with
strategizing and implementing global regulatory strategies for all
clinical and pre-clinical programs, in addition to co-leading the
Company’s CMC efforts. Ms. Peterson previously served as Senior
Vice President, Regulatory & Quality after joining Gossamer in
2018.
“Caryn’s leadership and deep regulatory expertise have been
crucial to the ongoing development of our clinical assets,
including seralutinib and GB004,” said Faheem Hasnain, Chairman,
President and CEO of Gossamer Bio. “Her keen strategic mindset and
strong relationships with regulatory agencies around the world will
continue to be tremendously valuable to Gossamer as we advance our
portfolio of clinical and pre-clinical programs.”
Previously, from 2004 to 2018, Ms. Peterson served as Managing
Partner of Development & Strategic Consulting (“DSC”)
Associates, LLC, focusing on the development, integration, and
implementation of global clinical and regulatory strategy across a
broad range of therapeutic areas. From 2008 to 2018, Ms. Peterson
also served as Vice President, Regulatory Affairs at Syndax
Pharmaceuticals, Inc. From 1997 to 2004, Ms. Peterson served as
Vice President of Regulatory Affairs at FeRx Incorporated, and from
1989 to 1997, Ms. Peterson held managerial positions in both
Pharmaceutical Development and Regulatory Affairs at Amylin
Pharmaceuticals. Prior to joining Amylin, Ms. Peterson was a staff
scientist at Hybritech Incorporated from 1981 to 1989. Ms. Peterson
has coauthored several research publications and is a co-inventor
on multiple patent applications.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company
focused on discovering, acquiring, developing and commercializing
therapeutics in the disease areas of immunology, inflammation and
oncology. Its goal is to be an industry leader in each of these
therapeutic areas and to enhance and extend the lives of patients
suffering from such diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210416005088/en/
For Investors and Media: Bryan Giraudo, Chief Financial
Officer Gossamer Bio Investor Relations ir@gossamerbio.com
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Apr 2023 to Apr 2024